TrialDiabetes, obesity & metabolism2022

Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, randomized controlled BEYOND-V trial.

What the trial testedas reported · 12 people · 2022

Range includes no effect

−0.01percentage points−0.20 to +0.17

As reported

difference −0.01 %, 95% CI −0.20 to 0.17

the abstract, start to end

… respectively (estimated difference -0.01%; 95% CI -0.20%, 0.17% …

← favours treatmentfavours comparator →

could be chance

Glycemic control

−0.01−0.20 to 0.17

MetforminGlycemic control

1 / 3

2022

2023

2024

this papertrialcites it